Alpha 2.0
Login Register
» Authors » Jan Paul de Boer

Jan Paul de Boer

Explore the profile of Jan Paul de Boer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2185
Followers 0
Related Specialties
Oncology
General Surgery
Radiology
Top 10 Co-Authors
Flora E van Leeuwen
Charlotte L Zuur
Daphne de Jong
Alfons J M Balm
Abrahim Al-Mamgani
Berthe M P Aleman
Michael Hauptmann
Coen R N Rasch
Pieternella J Lugtenburg
Arash Navran
Published In
Head Neck
Blood
Radiother Oncol
J Clin Oncol
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
41.
Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial
Driessen C, Groenewoud J, de Boer J, Gelderblom H, van der Graaf W, Prins J, et al.
Support Care Cancer . 2017 Dec; 26(4):1233-1242. PMID: 29230548
Purpose: The CONDOR study showed that docetaxel/cisplatin/5-fluorouracil (TPF) followed by conventional radiotherapy with cisplatin 100 mg/m on days 1, 22, and 43 (cis100 + RT; n = 27)) versus accelerated...
42.
Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors
van Eggermond A, Schaapveld M, Janus C, de Boer J, Krol A, Zijlstra J, et al.
Br J Cancer . 2017 Jun; 117(3):306-314. PMID: 28632726
Background: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk...
43.
Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design
Rigter L, Spaander M, Moons L, Bisseling T, Aleman B, de Boer J, et al.
BMC Cancer . 2017 Feb; 17(1):112. PMID: 28173773
Background: Second primary malignancies are a major cause of excess morbidity and mortality in cancer survivors. Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy and/or high-dose procarbazine have an...
44.
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma
Schaapveld M, Aleman B, van Eggermond A, Janus C, Krol A, van der Maazen R, et al.
N Engl J Med . 2015 Dec; 373(26):2499-511. PMID: 26699166
Background: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of...
45.
Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy
Theunissen E, Zuur C, Jozwiak K, Lopez-Yurda M, Hauptmann M, Rasch C, et al.
JAMA Otolaryngol Head Neck Surg . 2015 Aug; 141(9):810-5. PMID: 26291150
Importance: Patients with head and neck cancer may experience chemoradiotherapy-induced hearing loss, but the weighing of involved variables has been subjective. Identification of patient and treatment characteristics to predict the...
46.
Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group
Stoker S, Wildeman M, Novalic Z, Fles R, van der Noort V, de Bree R, et al.
Eur Arch Otorhinolaryngol . 2015 May; 273(6):1557-67. PMID: 25929413
This study estimated the value of quantitative measurements of EBV markers in the clinical management of nasopharyngeal carcinoma in a non-endemic area. The aim was to predict prognosis and detect...
47.
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma
Stoker S, Novalic Z, Wildeman M, Huitema A, Verkuijlen S, Juwana H, et al.
J Cancer Res Clin Oncol . 2015 Apr; 141(10):1845-57. PMID: 25920375
Purpose: Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25-34 %. Treatment options are limited, and survival is poor. Intratumoural Epstein-Barr virus (EBV) was...
48.
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
Van der Linden N, Buter J, Pescott C, Lalisang R, de Boer J, de Graeff A, et al.
Eur Arch Otorhinolaryngol . 2015 Apr; 273(2):455-64. PMID: 25876000
For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), chemotherapy can prolong life and alleviate symptoms. However, expected gains may be small, not...
49.
Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer
Heukelom J, Lopez-Yurda M, Balm A, Wijers O, Buter J, Gregor T, et al.
Head Neck . 2015 Mar; 38 Suppl 1:E488-93. PMID: 25728984
Background: The radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) phase III trial compared intra-arterial (IA) to intravenous (IV) cisplatin-based chemoradiation for head and neck cancer. Long-term efficacy and...
50.
Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study
Theunissen E, Zuur C, Yurda M, van der Baan S, Kornman A, de Boer J, et al.
J Otolaryngol Head Neck Surg . 2014 Aug; 43:30. PMID: 25095702
Background: Radiation to the inner ear may lead to (irreversible) sensorineural hearing loss. The purpose of this study was to evaluate the long-term effect of radiotherapy on hearing in patients...